Catalog No.
DHC35901
Expression system
Mammalian Cells
Species reactivity
Human
Isotype
A recombinant factor VIIa (rFVIIa) analog with three amino acid substitutions (Asp158Val, Val296Glu, and Glu298Met).
Clonality
Monoclonal
Target
F7, Proconvertin, SPCA, Serum prothrombin conversion accelerator, Coagulation factor VII, Eptacog alfa
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P08709
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
rFVIIa analog NN1731, FVIIa DVQ, Eptacog Alfa
Clone ID
Vatreptacog alfa
The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity., PMID:37915568
Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue., PMID:31506285
The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides., PMID:29758051
Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools., PMID:28077675
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity., PMID:26362483
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa., PMID:24931322
Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia., PMID:22757678
Vatreptacog alfa from conception to clinical proof of concept., PMID:22510860
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial., PMID:22470921
Hemostatic properties of the FVIIa analog NN1731., PMID:22446168
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays., PMID:21681082
For research use only. Not for human or drug use.
